Label Image (Lbl500903639)
Xarelto Tablet, Film Coated
Product Images NDC 50090-3639
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Xarelto (NDC 50090-3639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Xarelto 01)
This appears to be a statistical chart showing various comparisons between the drugs rivoxaban and warfarin. The chart details hazard ratios and confidence intervals for both drugs in relation to several variables such as age, gender, weight, and more.*
Figure 2 (Xarelto 02)
The text seems to be a table with various factors including age, sex, weight, region, medical history, and bleeding risk being analyzed for their impact on bleeding incidence in individuals taking XARELTO plus aspirin compared to taking aspirin alone. It is not clear what the values in the table represent without further context.*
Chemical Structure (Xarelto 03)
Figure 3 (Xarelto 04)
This text contains pharmacokinetic data for different subpopulations based on certain clinical characteristics. The text reports the fold change and 90% confidence interval in PK parameters such as AUC and Cmax for the subpopulations defined by End-Stage Renal Disease, Renal Impairment, Age, Body Weight, and Hepatic Impairment. The PK parameters were assessed for different subpopulations based on normal values and the relative change in these parameters is presented. The text also includes a note on the reference population and the dosage of the drug administered.*
Figure 4 (Xarelto 05)
This is a table showing the fold change in pharmacokinetics and 90 percent confidence intervals of various drugs when taken in combination with different inhibitors or inducers. The drugs include aspirin, atorvastatin, clarithromycin, clopidogrel, digoxin, enoxaparin, erythromycin, fluconazole, ketoconazole, midazolam, naproxen, omeprazole, ranitidine, and rifampicin. The inhibitors and inducers include strong and moderate inhibitors of the CYP3A enzyme and P-glycoprotein. The table also shows the change in pharmacokinetics relative to rivaroxaban alone.*
Figure 5 (Xarelto 06)
The text describes a chart showing Cumulative Event Rates (%) for XARELTO and Warfarin along with HR (95% CI) and the number of subjects at risk. The chart also displays the days from Randommization. However, the data in the chart is not useful as the values are not clearly mentioned.*
Figure 6 (Xarelto 07)
Figure 7 (Xarelto 08)
The text provided seems to be a graph or chart, showing cumulative event rates over time for various treatments. It is not possible to generate a useful description with this text.*
Figure 8 (Xarelto 09)
Figure 9 (Xarelto 10)
Figure 10 (Xarelto 11)
Figure 11 (Xarelto 12)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
